Brief Description
The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Estimated Enrollment
68 patients globally
Estimated End Date
August 2023
Trial is for people with
C3 Glomerulopathy (C3G)
Study Goal
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to placebo and standard of care in patients ...
What is involved for the patient?
Patients will be asked to attend a screening visit to assess eligibly. Medical history will be collected. The study team will collect ...
About the drug or intervention
LNP023/iptacopan is an investigational drug that we are studying as a potential targeted treatment for people with C3G and other ...